These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 33748950)
1. Cerebral aspergillosis in a patient on ibrutinib therapy. Creuzet E; Nourrisson C; Chaleteix C; Poirier P; Moniot M Br J Haematol; 2021 Jun; 193(6):1025. PubMed ID: 33748950 [No Abstract] [Full Text] [Related]
2. [Aspergillus spondylodiscitis in a patient treated with ibrutinib]. Petitdemange A; Martin A; Ruch Y; Chatron E; Karol A; Hansmann Y Med Mal Infect; 2020 May; 50(3):296-297. PubMed ID: 31722863 [No Abstract] [Full Text] [Related]
3. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis. Molica S; Baumann T; Giannarelli D Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324 [No Abstract] [Full Text] [Related]
4. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis. Molica S; Giannarelli D; Baumann T; Montserrat E Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067 [No Abstract] [Full Text] [Related]
5. An oral drug for chronic lymphocytic leukemia. Koehler A JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837 [TBL] [Abstract][Full Text] [Related]
6. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543 [No Abstract] [Full Text] [Related]
7. Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma. Shulman K; Kazarin O; Tannous E; Sofer O Isr Med Assoc J; 2021 Jun; 23(6):385-386. PubMed ID: 34155856 [No Abstract] [Full Text] [Related]
8. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia. Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651 [No Abstract] [Full Text] [Related]
13. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia. İskender G; İskender D; Ertek M Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674 [No Abstract] [Full Text] [Related]
14. Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib. Brener ZZ; Brener H; Losev A J Oncol Pharm Pract; 2020 Oct; 26(7):1735-1737. PubMed ID: 32054411 [TBL] [Abstract][Full Text] [Related]
15. Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates. Saling C; Feller F; Vikram HR BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33468501 [TBL] [Abstract][Full Text] [Related]
17. Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? Gaye E; Le Bot A; Talarmin JP; Le Calloch R; Belaz S; Dupont M; Tattevin P Med Mal Infect; 2018 Jun; 48(4):294-297. PubMed ID: 29402474 [No Abstract] [Full Text] [Related]